北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学公共卫生学院  > 期刊论文
学科主题: 公共卫生
题名:
Daclizumab for relapsing remitting multiple sclerosis
作者: Liu, Jia1; Wang, Luning1; Zhan, Siyan2; Tan, Jiping1; Xia, Yinyin2
刊名: COCHRANE DATABASE OF SYSTEMATIC REVIEWS
发表日期: 2010
DOI: 10.1002/14651858.CD008127.pub2
期: 6
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: DIAGNOSTIC-CRITERIA ; INTERFERON-BETA ; ANTIBODY ; GUIDELINES ; CELLS
英文摘要:

Background

The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.

Objectives

To assess the efficacy and safety of daclizumab for patients with relapsing remitting multiple sclerosis.

Search strategy

We searched the Cochrane Multiple Sclerosis Group trials register (September 2009), MEDLINE (January 1966 to September 2009), EMBASE (January 1985 to September 2009). At the same time, we handsearched the references quoted in the identified trials, reports (September 2009) from the most important neurological associations and MS Societies in Europe and America, contacted researchers who were participating in trials on daclizumab.

Selection criteria

All randomized controlled clinical trials (RCTs) evaluating daclizumab, alone or combined with other treatments versus placebo, or any other treatment for patients with RRMS. Both parallel group and cross-over designs were included. Data collection and analysis Two reviewers independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional information. Adverse effects information was collected from the trials.

Main results

We found no study meeting our inclusion criteria.

Authors′ conclusions

Although studies examining daclizumab for relapsing remitting multiple sclerosis were located, methodologic limitations resulted in the exclusion of all studies. Some of the studies were labelled as crossover trials, however they only compared the effect of different interventions for the same individual. The true randomized crossover trial should compare the effect of different groups, which receive the same intervention, only with the difference in sequence. In other words, the crossover comparison should be between the different groups, rather than on the individual between pretreatment and post treatment. At the same time, all the individuals should be randomly allocated to different groups. There was also a rigorous randomized controlled trial, but the follow-up was shorter than one year (only 44 weeks). In general, daclizumab is safe and well tolerated in combination of interferon treated multiple sclerosis population. Improvements in methodology in future studies are required for meaningful synthesis of data.

语种: 英语
项目资助者: Department of Geriatric Neurology, Chinese PLA General Hospital, China
WOS记录号: WOS:000278858300037
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/60754
Appears in Collections:北京大学公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Neurol, Beijing 100853, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100871, Peoples R China

Recommended Citation:
Liu, Jia,Wang, Luning,Zhan, Siyan,et al. Daclizumab for relapsing remitting multiple sclerosis[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2010(6).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Liu, Jia]'s Articles
[Wang, Luning]'s Articles
[Zhan, Siyan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Liu, Jia]‘s Articles
[Wang, Luning]‘s Articles
[Zhan, Siyan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace